Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 411

1.

A tumorigenic factor interactome connected through tumor suppressor microRNA-198 in human pancreatic cancer.

Marin-Muller C, Li D, Bharadwaj U, Li M, Chen C, Hodges SE, Fisher WE, Mo Q, Hung MC, Yao Q.

Clin Cancer Res. 2013 Nov 1;19(21):5901-13. doi: 10.1158/1078-0432.CCR-12-3776. Epub 2013 Aug 29.

2.

Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression.

Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q.

Mol Cancer. 2011 Aug 31;10:106. doi: 10.1186/1476-4598-10-106.

3.

MicroRNA-215 functions as a tumor suppressor and directly targets ZEB2 in human pancreatic cancer.

Li QW, Zhou T, Wang F, Jiang M, Liu CB, Zhang KR, Zhou Q, Tian Z, Hu KW.

Genet Mol Res. 2015 Dec 8;14(4):16133-45. doi: 10.4238/2015.December.8.2. Retraction in: Genet Mol Res. 2016 Dec 01;15(4):.

4.

MiR-371-5p facilitates pancreatic cancer cell proliferation and decreases patient survival.

He D, Miao H, Xu Y, Xiong L, Wang Y, Xiang H, Zhang H, Zhang Z.

PLoS One. 2014 Nov 20;9(11):e112930. doi: 10.1371/journal.pone.0112930. eCollection 2014.

5.

A decrease in miR-150 regulates the malignancy of pancreatic cancer by targeting c-Myb and MUC4.

Yang K, He M, Cai Z, Ni C, Deng J, Ta N, Xu J, Zheng J.

Pancreas. 2015 Apr;44(3):370-9. doi: 10.1097/MPA.0000000000000283.

PMID:
25522282
6.

Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation.

Bharadwaj U, Marin-Muller C, Li M, Chen C, Yao Q.

Carcinogenesis. 2011 Jul;32(7):1013-24. doi: 10.1093/carcin/bgr075. Epub 2011 Apr 23.

7.

Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.

Li L, Li Z, Kong X, Xie D, Jia Z, Jiang W, Cui J, Du Y, Wei D, Huang S, Xie K.

Gastroenterology. 2014 Aug;147(2):485-97.e18. doi: 10.1053/j.gastro.2014.04.048. Epub 2014 May 20.

PMID:
24859161
8.

MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2.

Sun Y, Zhang T, Wang C, Jin X, Jia C, Yu S, Chen J.

PLoS One. 2015 Apr 9;10(4):e0119783. doi: 10.1371/journal.pone.0119783. eCollection 2015. Erratum in: PLoS One. 2015;10(5):e0128257.

9.

miR-133a functions as a tumor suppressor and directly targets FSCN1 in pancreatic cancer.

Qin Y, Dang X, Li W, Ma Q.

Oncol Res. 2013;21(6):353-63. doi: 10.3727/096504014X14024160459122.

PMID:
25198665
10.

Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.

Liu J, Ma J, Wu Z, Li W, Zhang D, Han L, Wang F, Reindl KM, Wu E, Ma Q.

BMC Cancer. 2014 Sep 20;14:686. doi: 10.1186/1471-2407-14-686.

11.

Pre-B-cell leukemia transcription factor 1 regulates expression of valosin-containing protein, a gene involved in cancer growth.

Qiu Y, Tomita Y, Zhang B, Nakamichi I, Morii E, Aozasa K.

Am J Pathol. 2007 Jan;170(1):152-9.

12.

Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling.

Li J, Wu H, Li W, Yin L, Guo S, Xu X, Ouyang Y, Zhao Z, Liu S, Tian Y, Tian Z, Ju J, Ni B, Wang H.

Oncogene. 2016 Oct 20;35(42):5501-5514. doi: 10.1038/onc.2016.90. Epub 2016 Apr 11.

13.

The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival.

Deng J, He M, Chen L, Chen C, Zheng J, Cai Z.

PLoS One. 2013 Oct 8;8(10):e76450. doi: 10.1371/journal.pone.0076450. eCollection 2013.

14.

MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro.

Huang FT, Peng JF, Cheng WJ, Zhuang YY, Wang LY, Li CQ, Tang J, Chen WY, Li YH, Zhang SN.

Dig Dis Sci. 2017 Apr;62(4):944-957. doi: 10.1007/s10620-017-4472-7. Epub 2017 Feb 13.

PMID:
28194669
15.

MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3.

Chang W, Liu M, Xu J, Fu H, Zhou B, Yuan T, Chen P.

Tumour Biol. 2016 Nov;37(11):14813-14824. Epub 2016 Sep 16.

PMID:
27638830
16.

KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis.

Yuan P, He XH, Rong YF, Cao J, Li Y, Hu YP, Liu Y, Li D, Lou W, Liu MF.

Cancer Res. 2017 Jan 1;77(1):100-111. doi: 10.1158/0008-5472.CAN-16-1898. Epub 2016 Oct 28.

PMID:
27793842
17.

Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.

Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, Lee DH, Subleski J, Chan T, Weiss JM, Back TC, Yanaga K, Hanna N, Alexander HR, Maitra A, Hussain SP.

Int J Cancer. 2013 Feb 15;132(4):785-94. doi: 10.1002/ijc.27736.

18.

miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.

Zhang ZL, Bai ZH, Wang XB, Bai L, Miao F, Pei HH.

PLoS One. 2015 Mar 5;10(3):e0118814. doi: 10.1371/journal.pone.0118814. eCollection 2015.

19.

Targeting miR-21 for the therapy of pancreatic cancer.

Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P.

Mol Ther. 2013 May;21(5):986-94. doi: 10.1038/mt.2013.35. Epub 2013 Mar 12.

20.

ZFP36L2 promotes cancer cell aggressiveness and is regulated by antitumor microRNA-375 in pancreatic ductal adenocarcinoma.

Yonemori K, Seki N, Kurahara H, Osako Y, Idichi T, Arai T, Koshizuka K, Kita Y, Maemura K, Natsugoe S.

Cancer Sci. 2017 Jan;108(1):124-135. doi: 10.1111/cas.13119.

Supplemental Content

Support Center